Gender, ethnicity, and genes in cardiovascular disease. Part 2: Implications for pharmacotherapy

Heart Disease

Volumn 5, Issue 3, 2003, Pages 202-214

  Schaefer, Benjamin M ^a   Caracciolo, Vincent ^b   Frishman, William H ^c   Charney, Pamela ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NORWALK HOSPITAL   (United States)

Author keywords

Cardiovascular pharmacology; Ethnicity; Race factors; Sex factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; ENCAINIDE; FIBRINOLYTIC AGENT; HEPARIN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; ORAL CONTRACEPTIVE AGENT; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TIMOLOL; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; WARFARIN;

ALLERGIC PNEUMONITIS; ANORGASMIA; ASIAN; BLEEDING; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; COUGHING; ETHNOLOGY; FRACTURE; GENDER; GENE; GOUT; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPOKALEMIA; HYPONATREMIA; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LONG QT SYNDROME; LUNG EDEMA; ORTHOSTATIC HYPOTENSION; REVIEW; SIDE EFFECT; SOUTHEAST ASIA; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOSIS; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ANTILIPEMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, ANGIOTENSIN; SEX CHARACTERISTICS;

EID: 0037734019     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000074437.07268.00     Document Type: Review

References (150)

1. Schaefer B, Carraciolo V, Frishman W, Charney P. Gender, ethnicity and genetics in cardiovascular disease. Part 1: Basic principles. Heart Disease. 2003;March/April:5.
2. Wood AJJ. Racial differences in the response to drugs - pointers to genetic differences (editorial). N Engl J Med. 2001;344:1393-1394.
3. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(Suppl):1-26.
4. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993;329:292-296.
5. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.
6. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682-1688.
7. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
8. Edwards LD. Acceptability of foreign data: genetic, cultural and environmental differences - do they matter? In: Walker SR, McAuslane N, Lumley CE, McAuslane JAN, ed. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Hingham, MA: Kluwer Academic Publishers; 1994:2-11.
9. Zhou HH, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989;320:565-570.
10. Naito C. Evaluation methods for clinical trials of drugs in Japan which may affect ethnic differences. In: Walker SR, McAuslane N, Lumley CE, McAuslane JAN, ed. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Hingham, MA: Kluwer Academic Publishers; 1994:49-62.
11. Henderson J. Medical practice differences between Europe, the United States and Japan. In: Walker SR, McAuslane N, Lumley CE, McAuslane JAN, ed. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Hingham, MA: Kluwer Academic Publishers; 1994:97-106.
12. Naito C. Ethnic effects on pharmacokinetic parameters. In: Walker SR, McAuslane N, Lumley CE, McAuslane JAN, ed. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Hingham, MA: Kluwer Academic Publishers; 1994:161-177.
13. Harrison P. Herbal medicine takes root in Germany. Can Med Assoc J. 1998;158:637-639.
14. Wagner H. Phytomedicine research in Germany. Environ Health Perspect. 1999;107:779-781.
15. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine. 2001;8:152-160.
16. Goldin BR, Adlercreutz H, Gorbach SL, et al. The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. Am J Clin Nutr. 1986;44:945-953.
17. Ballagh S. Alcohol: The link between hormone replacement and breast cancer risk. Womens Health Issues. 1999;9:338-342.
18. Frishman WH, Cheng-Lai A, Spiegel A, et al. Appendix 7: Pharmacokinetic changes, route of elimination, and dosage adjustment of selected cardiovascular drugs in the elderly. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York: McGraw Hill; 2003:1033-1036.
19. Chien PC, Frishman WH: Lipid disorders. In: Crawford MH, ed. Current Diagnosis and Treatment in Cardiology. 2nd ed. New York: McGraw Hill; 2003:15-30.
20. Walsh JME. Lipids: natural history and pharmacologic management. In: Charney, P, ed. Coronary Artery Disease in Women. Philadelphia, PA: American College of Physicians; 1999.
21. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
22. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
23. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Group. Prevention of coronary heart diseae with pravastatin in men with hypercholesteremia. N Engl J Med. 1995;333:1301-1307.
24. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
25. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
26. Frick MH, Elo U, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
27. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001;10:971-981.
28. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
29. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. 2001;357:509-512.
30. Poulter NR, Caulfield M, Feder G. Ethnic variations in response to a statin (EVIREST). J Hum Hypertens. 2001;15:S87-S89.
31. Muck W, Unger S, Kawano K, Ahr G. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol. 1998;45:583-590.
32. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J. 1996;131:1184-1191.
33. Anonymous. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
34. Anastos K, Charney P, Charon RA, et al. Hypertension in women: what is really known?The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287-293.
35. Walle T, Walle UK, Cowart TD, et al. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46:257-263.
36. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001;103:375-380.
37. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
38. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
39. Adams KF Jr, Sueta CA, Gheorfhiade MN, et al. Gender differences in survival in advanced heart failure: insights from the FIRST study. Circulation. 1999;99:1816-1821.
40. Walle T, Byington RP, Furberg CD, et al. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther. 1985;38:509-18.
41. Sowinski KM, Lima JJ, Burlew BS, et al. Racial differences in propranolol enantiomer kinetics following simultaneous i. v. and oral administration. Br J Clin Pharmacol. 1996;42:339-346.
42. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
43. Lucas C, Jenkins P, Mendels J, et al. The effectiveness of labetalol compared to hydrochlorothiazide in hypertensive black patients. J Natl Med Assoc. 1991;83:866-871.
44. Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/betablockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990;48:665-675.
45. Saunders E, Curry C, Hinds J, et al. Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens. 1987;3:294-302.
46. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos. 1996;24:350-355.
47. Radevski IV, Valtchanova SP, Candy GP, et al. Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. Am J Cardiol. 1999;:34:70-75.
48. Anonymous. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
49. Huang J, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther. 1999;65:402-407.
50. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymerphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica. 1986;16:435-447.
51. Lewis RV, Lennard MS, Jackson PR, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1985;19:329-333.
52. Lennard MS, Lewis RV, Brawn LA, et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol. 1989;27:429-434.
53. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219-230.
54. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther. 2000;68:286-292.
55. Ahsan CH, Renwick AG, Waller DG, et al. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther. 1993;54:329-338.
56. Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther. 2000;68:130-142.
57. Sowunmi A, Rashid TJ, Akinyinka OO, et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol. 1995;40:489-493.
58. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
59. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
60. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
61. Francis GS, Cohn JN, Johnson G, et al for the V-HeFT VA Cooperative Studies Group: Plasma norepinephrine, plasma rennin activity, and congestive heart failure: relation to survival and the effects of therapy in V-HeFTII. Circulation. 1993;87(suppl VI):VI-40.
62. Wenger N. Natural history of coronary artery disease in women: Epidemiology, coronary risk factors, and clinical characteristics. In: Charney P, ed. Coronary Artery Disease in Women: What All Physicians Need to Know. Philadelphia: American College of Physicians; 1999:5.
63. Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol. 1997;29:35-42.
64. Ghali WA, Faris PD, Galbraith PD, et al. Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data. Ann Intern Med. 2002;136:723-732.
65. Mehilli J, Kastrati A, Dirschinger J, et al. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. JAMA. 2002;287:210-215.
66. Nakamura Y, Moss AJ, Brown MW, et al. Ethnicity and long-term outcome after an acute coronary event. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:500-506.
67. Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation. 2000;101:2231-2238.
68. Chen J, Rathore SS, Radford MJ, et al. Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med. 2001;344:1443-1449.
69. Peterson ED, Shaw LK, DeLong ER, et al. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med. 1997;336:480-486.
70. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340:618-626.
71. Borzak S, Joseph C, Havstad S, et al. Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? Am Heart J. 1999;137:338-345.
72. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke. 2001;32:1061-1068.
73. Manhapra A, Canto JG, Barron HV, et al. Underutilization of reperfusion therapy in eligible African Americans with acute myocardial infarction: role of presentation and evaluation characteristics. Am Heart J. 2001;142:604-610.
74. Sane DC, Stump DC, Topol EJ, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Circulation. 1991;83:170-175.
75. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943-1951.
76. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521-527.
77. Buring JE, Hennekens CH. Randomized trials of primary prevention of cardiovascular disease in women. An investigator's view. Ann Epidemiol. 1994;4:111-114.
78. Anonymous. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349-360.
79. Lawlor DA, Bedford C, Taylor M, et al. Aspirin use for the prevention of cardiovascular disease: the British Women's Heart and Health Study. Br J Gen Pract. 2001;51:743-745.
80. Morikawa M, Kojima T, Inoue M, et al. Sex difference in the effect of aspirin on rat platelet aggregation and arachidonic acid metabolism. Jpn J Pharmacol. 1985;37:317-323.
81. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke. 1989;20:34-37.
82. Baron WM, Lindheimer MD. Medical Disorders During Pregnancy. 2nd ed. St. Louis: Mosby; 1995.
83. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation. 1996;94:2083-2089.
84. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, et al. Refining the treatment of women with unstable angina-a randomized, double-blind, comparative safety and efficacy evaluation of integrelin versus aspirin in the management of unstable angina. Clin Cardiol. 1996;19:869-874.
85. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77:748-754.
86. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol. 2000;36:381-386.
87. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
88. Emudianughe TS, Oduleye SO, Ebadan EE, et al. Sex differences in salicylic acid metabolism in Nigerian subjects. Xenobiotica. 1986;16:177-179.
89. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
90. Yu HC, Chan TY, Critchley JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. Quart J Med. 1996;89:127-135.
91. Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood. 2001;98:2584-2587.
92. Campbell NR, Hull RD, Brant R, et al. Different effects of heparin in males and females. Clin Invest Med. 1998;21:71-78.
93. Wolbrette D, Patel H. Arrhythmias and women. Curr Opin Cardiol. 1999;14:36-43.
94. Burke JH, Ehlert FA, Kruse JT, et al. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol. 1997;79:178-181.
95. Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol. 1997;29:93-99.
96. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidineinduced QTc interval prolongation in women. Clin Pharmacol Ther. 2000;67:413-418.
97. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol. 1998;81:869-876.
98. Rodriguez I, Kilborn MJ, Liu X-K, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-1326.
99. Rosano GM, Leonardo F, Sarrel PM, et al. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347:786-788.
100. Hnatkova K, Waktare JE, Murgatroyd FD, et al. Age and gender influences on rate and duration of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1998;21:2455-2458.
101. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
102. th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;553-566.
103. August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab. 1999;84:1862-1866.
104. Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483-489.
105. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999;180:S357-S363.
106. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999;180:S375-S382.
107. Anonymous. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985;291:97-104.
108. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787-1793.
109. th ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
110. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
111. Anonymous. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
112. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6. 8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
113. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
114. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
115. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
116. Anonymous. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
117. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoidplacebo trial in healthy women. Circulation. 2002;106:1224-1228.
118. Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women? Ann Intern Med. 2002;136:529-533.
119. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 2001;285:906-913.
120. Wagner F, Jahnchen E, Trenk D, et al. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine. Klin Wochenschr. 1987;65:1164-1168.
121. Fleishaker JC, Pearson LK, Pearson PG, et al. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. J Clin Pharmacol. 1999;39:260-267.
122. Sorensen MB, Collins P, Ong PJ, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. 2002;106:1646-1651.
123. Anonymous. Freely associating. Nat Genet 1999;22:1-2.
124. Anonymous Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. JAMA 1982;248:1996-2003.
125. Weaver WD, White HD, Wilcox RG, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA. 1996;275:777-782.
126. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987;75:785-791.
127. Chow MS, White CM, Lau CP, et al. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. J Clin Pharmacol. 2001;41:92-96.
128. Funck-Brentano C, Turgeon J, Woosley RL, et al. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989;249:134-142.
129. Flockhart DA. www.georgetown.edu/departments/pharmacology/davetab.html, (accessed 6/15/2001).
130. Camm AJ, Karam R, Pratt CM. The Azimilide Post-infarct Survival Evaluation (ALIVE) trial. Am J Cardiol 1998;81:35D-39D.
131. Corey A, Agnew J, Bao J, et al. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. J Clin Pharmacol. 1997;37:946-953.
132. Wilson JD. Antinuclear antibodies and cardiovascular drugs. Drugs. 1980;19:292-305.
133. Koup JR, Abel RB, Smithers JA, et al. Effect of age, gender, and race on steady state procaimimide pharmacokinetics after administration of procanbid sustained-release tablets. Ther Drug Monitor. 1998;20:73-77.
134. Mikus G, Gross AS, Beckmann J, et al. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther. 1989;45:562-567.
135. Os I, Bratland B, Dahlof B, et al. Female sex as an important determinant of lisinopril-induced cough. Lancet. 1992;339:372.
136. Hu OY, Ding PY, Huang CS, et al. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration. J Clin Pharmacol. 1997;37:834-840.
137. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
138. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219-230.
139. Lally EV, Ho G Jr., Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med. 1986;146:2221-2225.
140. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. Can Med Assoc J. 1991;145:28-34.
141. Stevenson JG, Umstead GS. Sexual dysfunction due to antihypertensive agents. Drug Intell Clin Pharm. 1984;18:113-121.
142. Lando HA, Gritz ER. Smoking cessation techniques. J Am Med Womens Assoc 1996;51:31-447.
143. Talbot S, Smith AJ. Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure. Br Heart J. 1975;37:1059-1063.
144. Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1980;1:1107-1109.
145. Anonymous. Drugs that cause sexual dysfunction: an update. Med Lett. 1992;34:73-78.
146. Anonymous. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115-1122.
147. Tam GS, Marks GS, Brien JF, et al. Sex- and species-related differences in the biotransformation of isosorbide dinitrate by various tissues of the rabbit and rat. Can J Physiol Pharmacol. 1987;65:1478-1483.
148. Bennett BM, Twiddy DA, Moffat JA, et al. Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood. Biochem Pharmacol. 1983;32:3729-3734.
149. Vincent J, Elliott HL, Meredith PA, et al. Racial differences in drug responses-a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans. Br J Clin Pharmacol. 1986;21:401-408.
150. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. N Engl J Med. 1999;341:217.